AbbVie (ABBV) EV to CFO (2012 - 2026)
AbbVie's (ABBV) quarterly EV to CFO came in at 127.52 in Q2 2026, up 104.4% year-over-year from 62.39 in Q2 2025, and up 30.24% quarter-over-quarter from 97.91 in Q1 2026.
Analysis
AbbVie (ABBV) EV to CFO (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported EV to CFO for 15 consecutive years, with 127.52 the latest figure, recorded in Q2 2026.
- On a quarterly basis, EV to CFO rose 104.4% year-over-year to 127.52 in Q2 2026; TTM through Jun 2026 was 22.46, a 34.73% increase from a year earlier, with the FY2025 full-year figure at 20.96, up 27.88% from the prior year.
- EV to CFO was 127.52 for Q2 2026 at AbbVie, up from 97.91 in the prior quarter.
- Over five years, EV to CFO peaked at 223.22 in Q1 2025 and troughed at 29.66 in Q3 2022.
- A 5-year average of 73.31 and a median of 59.92 in 2025 frame the typical range for EV to CFO.
- Across the five-year window, EV to CFO surged 252.07% in 2024 and slumped 56.14% in 2026, its largest moves.
- Over 5 years, EV to CFO stood at 37.26 in 2022, then soared by 47.37% to 54.91 in 2023, then dropped by 20.36% to 43.73 in 2024, then surged by 74.78% to 76.43 in 2025, then surged by 66.85% to 127.52 in 2026.
- The last three EV to CFO figures came in at 127.52 (Q2 2026), 97.91 (Q1 2026), and 76.43 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 127.52 |
| Mar 31, 2026 | 97.91 |
| Dec 31, 2025 | 76.43 |
| Sep 30, 2025 | 57.46 |
| Jun 30, 2025 | 62.39 |
| Mar 31, 2025 | 223.22 |
| Dec 31, 2024 | 43.73 |
| Sep 30, 2024 | 62.74 |
| Jun 30, 2024 | 127.63 |
| Mar 31, 2024 | 75.13 |
| Dec 31, 2023 | 54.91 |
| Sep 30, 2023 | 33.00 |
| Jun 30, 2023 | 36.25 |
| Mar 31, 2023 | 65.46 |
| Dec 31, 2022 | 37.26 |
| Sep 30, 2022 | 29.66 |
| Jun 30, 2022 | 52.12 |
| Mar 31, 2022 | 56.83 |
| Dec 31, 2021 | 45.26 |
| Sep 30, 2021 | 22.49 |